A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans

Cell

Volumn 119, Issue 5, 2004, Pages 591-602

  Bond, Gareth L ^b   Hu, Wenwei ^b   Bond, Elisabeth E ^b   Robins, Harlan ^a   Lutzker, Stuart G ^b   Arva, Nicoleta C ^g   Bargonetti, Jill ^g   Bartel, Frank ^d   Taubert, Helge ^d   Wuerl, Peter ^e   Onel, Kenan ^f   Yip, Linwah ^c   Hwang, Shih Jen ^c   Strong, Louise C ^c   Lozano, Guillermina ^c   Levine, Arnold J ^a,b  

^a INSTITUTE FOR ADVANCED STUDY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e UNIVERSITY OF ULM   (Germany)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; RNA; TRANSCRIPTION FACTOR SP1; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; ATTENUATION; CARCINOGENESIS; CONTROLLED STUDY; FAMILIAL CANCER; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 8844278362     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2004.11.022     Document Type: Article

References (30)

1. Blume S.W., Snyder R.C., Ray R., Thomas S., Koller C.A., Miller D.M. Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J. Clin. Invest. 88:1991;1613-1621
2. Cordon-Cardo C., Latres E., Drobnjak M., Oliva M.R., Pollack D., Woodruff J.M., Marechal V., Chen J., Brennan M.F., Levine A.J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54:1994;794-799
3. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A. Jr., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:1992;215-221
4. Freedman D.A., Levine A.J. Regulation of the p53 protein by the MDM2 oncoprotein-thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res. 59:1999;1-7
5. Garber J.E., Friend S.H., Strong L.C., Patenaude A.F., Juengst E.T., Reilly P.R., Correa P., Fraumeni J.F. Jr., Frebourg T. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. J. Natl. Cancer Inst. 84:1992;1156-1160
6. Grinstein E., Jundt F., Weinert I., Wernet P., Royer H.D. Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene. 21:2002;1485-1492
7. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299
8. Honda R., Tanaka H., Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:1997;25-27
9. Hurtado J., Esbrit P. Treatment of malignant hypercalcaemia. Expert Opin. Pharmacother. 3:2002;521-527
10. Hwang S.J., Lozano G., Amos C.I., Strong L.C. Germline p53 mutations in a cohort with childhood sarcoma. sex differences in cancer risk Am. J. Hum. Genet. 72:2003;975-983
11. Jin S., Levine A.J. The p53 functional circuit. J. Cell Sci. 114:2001;4139-4140
12. Jones S.N., Roe A.E., Donehower L.A., Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 378:1995;206-208
13. Jones S.N., Hancock A.R., Vogel H., Donehower L.A., Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA. 95:1998;15608-15612
14. Knudson A.G. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer. 1:2001;157-162
15. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature. 387:1997;299-303
16. Lain S., Lane D. Improving cancer therapy by non-genotoxic activation of p53. Eur. J. Cancer. 39:2003;1053-1060
17. Landers J.E., Cassel S.L., George D.L. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res. 57:1997;3562-3568
18. Leach F.S., Tokino T., Meltzer P., Burrell M., Oliner J.D., Smith S., Hill D.E., Sidransky D., Kinzler K.W., Vogelstein B. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 53:1993;2231-2234
19. Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E., Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 250:1990;1233-1238
20. Lu W., Lin J., Chen J. Expression of p14ARF overcomes tumor resistance to p53. Cancer Res. 62:2002;1305-1310
21. Lundgren K., Montes de Oca Luna R., McNeill Y.B., Emerick E.P., Spencer B., Barfield C.R., Lozano G., Rosenberg M.P., Finlay C.A. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev. 11:1997;714-725
22. Mendrysa S.M., McElwee M.K., Michalowski J., O'Leary K.A., Young K.M., Perry M.E. mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol. Cell. Biol. 23:2003;462-472
23. Michael D., Oren M. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol. 13:2003;49-58
24. Momand J., Jung D., Wilczynski S., Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 26:1998;3453-3459
25. Montes de Oca Luna R., Wagner D.S., Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 378:1995;203-206
26. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 358:1992;80-83
27. Phelps M., Darley M., Primrose J.N., Blaydes J.P. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res. 63:2003;2616-2623
28. Ries S., Biederer C., Woods D., Shifman O., Shirasawa S., Sasazuki T., McMahon M., Oren M., McCormick F. Opposing effects of Ras on p53. transcriptional activation of mdm2 and induction of p19ARF Cell. 103:2000;321-330
29. Taubert H., Koehler T., Meye A., Bartel F., Lautenschlager C., Borchert S., Bache M., Schmidt H., Wurl P. mdm2 mRNA level is a prognostic factor in soft tissue sarcoma. Mol. Med. 6:2000;50-59
30. Zauberman A., Flusberg D., Haupt Y., Barak Y., Oren M. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res. 23:1995;2584-2592